Stratos Wealth Advisors LLC Sells 3,619 Shares of Johnson & Johnson (NYSE:JNJ)

Stratos Wealth Advisors LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 21.1% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 13,499 shares of the company's stock after selling 3,619 shares during the quarter. Stratos Wealth Advisors LLC's holdings in Johnson & Johnson were worth $2,239,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at $4,390,037,000. Raymond James Financial Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at $1,339,878,000. GAMMA Investing LLC lifted its position in shares of Johnson & Johnson by 24,450.4% during the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock valued at $1,196,596,000 after acquiring an additional 7,185,977 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Johnson & Johnson by 26.4% during the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock valued at $3,844,580,000 after acquiring an additional 4,842,582 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its position in shares of Johnson & Johnson by 134.5% during the 4th quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company's stock valued at $1,149,536,000 after acquiring an additional 4,559,147 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Down 0.5%

Shares of NYSE:JNJ traded down $0.82 during midday trading on Friday, hitting $156.87. 7,866,488 shares of the stock were exchanged, compared to its average volume of 8,077,942. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The business's fifty day simple moving average is $153.75 and its two-hundred day simple moving average is $154.49. The company has a market capitalization of $377.44 billion, a PE ratio of 17.45, a P/E/G ratio of 2.14 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. As a group, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.31%. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on JNJ shares. Wall Street Zen upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Finally, Guggenheim reaffirmed a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Eleven analysts have rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $171.00.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.